What is BPC-157?
BPC-157 is a synthetic 15-amino-acid peptide discussed in tissue-repair and gastrointestinal research. Animal and laboratory findings are extensive relative to the human evidence base.
Proposed mechanism
Preclinical papers describe nitric-oxide signalling, angiogenesis, growth-factor pathways, cell migration and inflammatory responses. No single therapeutic mechanism is established in humans.
What has been published?
Recent reviews describe decades of preclinical findings while emphasizing translational barriers including formulation, pharmacokinetics, reproducibility and the lack of mature clinical trials.
Current human evidence
Robust randomized controlled evidence establishing efficacy for common online claims is lacking.
Regulatory status
BPC-157 is not an FDA-approved drug. FDA has identified limited safety information and potential concerns including immunogenicity and peptide-related impurities.
Possible areas of research interest
- Tissue-repair biology
- Gastrointestinal research
- Angiogenesis and vascular signalling
- Inflammatory pathways
Important limitations
- Evidence is dominated by animal and laboratory studies
- No approved formulation or validated human regimen
- Long-term human safety is not established
- Online claims often exceed clinical evidence
References
AEVLI prioritizes primary publications and regulator materials over anecdotal claims.